The final stage of the clinical trial of the University of Oxford and AstraZeneca’s experimental vaccine is to begin from the next week. The final stage will take place in Pune.
“The phase III trial of Covishield vaccine will begin at Sassoon hospital from next week. It is likely to start on Monday.” Dr Muralidhar Tambe, Dean of Sassoon General Hospital, told the news agency PTI.
Tambe said that the third phase of a clinical trial will have around 150-200 volunteers with a dose of Covishield.
From Saturday, the Sassoon General Hospital in Pune will start enrolling volunteers.
The first phase trial results were published in The Lancet medical journal. It stated that the vaccine AZD1222 had a positive response and it did not have any serious side effects.
The researches added that this vaccine may have some minor side effects. However, they further added that some side effects could be removed by taking paracetamol.
The second phase of the trial was conducted at Bharti Vidyapeeth Medical College and King Edward Memorial Hospital in Pune. A drug maker who is Pune based signed a deal with AstraZeneca to manufacture COVID-19 vaccine by the University of Oxford.
AstraZeneca recently suspended the clinical trials in countries. On September 15, Serum Institute of India was granted permission to resume trials in India.
As per Lancet, the COVID-19 vaccine candidate developed by the Jenner Institute showed a positive result in its initial trial. It produced a dual immune response in people with an age range of 18 to 55.
The lead developer of the COVID-19 vaccine by the University of Oxford could come by the end of this year, however, it is not sure yet.
“The end of the year target for getting vaccine roll-out, it’s a possibility but there’s absolutely no certainty about that because we need three things to happen,” Sarah Gilbert earlier told.
Another trial of the COVID-19 vaccine by Novavax will begin by the Serum Institute of India in next month. This vaccine candidate doubled its potential COVID-19 vaccine manufacturing capacity to 2 million doses annually.